Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 9/20 | 0.38 |
| ▸ | TTK | P33981 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68403 | 0.72 | MAPK13 (0.43) | GAKFYNTTKAURKAAURKB | |
| SCHEMBL68401 | 0.68 | NPY5R (0.44) | PIK3CAGAKFYNTTKTGFBR1 | |
| SCHEMBL15507407 | 0.66 | TTK (0.47) | FYNTTK | |
| SCHEMBL28136363 | 0.65 | ALDH1A1 (0.74) | GAKTTKAURKAAURKBINCENP | |
| SCHEMBL15208222 | 0.65 | PTGS2 (0.49) | TGFBR1ACVR1DHFR | |
| SCHEMBL67138 | 0.64 | PDGFRB (0.44) | GAKTTKAURKAAURKBINCENP | |
| SCHEMBL69343 | 0.63 | MAPK14 (0.48) | — | |
| SCHEMBL2954606 | 0.63 | HSP90AA1 (0.41) | GAKTTKAURKAAURKBINCENP | |
| SCHEMBL1911998 | 0.63 | PDGFRB (0.51) | PIK3CAGAKPDGFRBPDGFRA | |
| SCHEMBL29368700 | 0.63 | PDGFRB (0.51) | PIK3CAGAKPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PIK3CA 30/4885MTOR 206/4885GAK 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.